Sitero Acquires Clario's eClinical Technology Suite
Sitero has announced its recent acquisition of a technology suite designed to manage the end-to-end clinical trial lifecycle. The newly acquired eClinical technology suite, formerly of Clario, will be integrated with Sitero's existing Mentor platform with plans to invest in AI to further streamline the clinical trial process. This combined suite offers tools designed to enhance efficiency, accuracy, and quality of data across the site, CRO, and sponsor lifecycle of clinical trials.
Key components of the technology platform include:
- Electronic Data Capture (EDC) and System
- Randomization and Trial Supply Management (RTSM)
- Clinical Trial Management System (CTMS)
- eTMF
- eConsent
- Site and Patient Payments
The Clario eClinical product suite will be rebranded and integrated into the Sitero Mentor platform. Sitero Mentor will continue to support the existing Clario customer base while further developing clinical solutions for new customers as well.
Reference
Sitero Acquires Clario's eClinical Technology Suite to Enhance Clinical Trial Delivery. (2023, August 1). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
